Vanguard Group Inc. increased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 52,721,795 shares of the medical research company's stock after acquiring an additional 339,522 shares during the period. Vanguard Group Inc. owned approximately 9.81% of Amgen worth $13,741,409,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the company. Community Bank N.A. increased its position in shares of Amgen by 2.0% during the fourth quarter. Community Bank N.A. now owns 15,804 shares of the medical research company's stock worth $4,119,000 after acquiring an additional 305 shares during the last quarter. Napatree Capital LLC grew its stake in Amgen by 66.4% during the 4th quarter. Napatree Capital LLC now owns 2,655 shares of the medical research company's stock valued at $692,000 after purchasing an additional 1,059 shares in the last quarter. Meridian Wealth Advisors LLC increased its holdings in Amgen by 0.7% during the 4th quarter. Meridian Wealth Advisors LLC now owns 8,164 shares of the medical research company's stock worth $2,128,000 after purchasing an additional 54 shares during the last quarter. Stevens Capital Management LP acquired a new position in shares of Amgen in the 4th quarter valued at approximately $1,785,000. Finally, Richwood Investment Advisors LLC boosted its stake in shares of Amgen by 5.0% during the 4th quarter. Richwood Investment Advisors LLC now owns 4,338 shares of the medical research company's stock valued at $1,131,000 after buying an additional 206 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have commented on AMGN shares. UBS Group reiterated a "hold" rating on shares of Amgen in a research note on Wednesday, February 12th. Bank of America increased their price target on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft cut their price objective on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Leerink Partners decreased their target price on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Finally, Piper Sandler raised their price objective on Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $314.04.
Check Out Our Latest Stock Analysis on AMGN
Insider Transactions at Amgen
In other news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. The trade was a 40.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now owns 28,987 shares in the company, valued at $8,496,669.44. This represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by insiders.
Amgen Price Performance
Shares of NASDAQ AMGN traded up $0.41 during mid-day trading on Thursday, reaching $306.12. The company had a trading volume of 263,732 shares, compared to its average volume of 2,536,430. The company has a 50-day moving average price of $299.66 and a two-hundred day moving average price of $298.46. The stock has a market cap of $164.45 billion, a PE ratio of 40.56, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.
Amgen Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.11%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio is currently 126.09%.
About Amgen
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Stories
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
